NanoViricide's EKC Eye Drug Candidate Stopped Clinical Conjunctivitis Pathology

WEST HAVEN, Conn.--(BUSINESS WIRE)--Jul 14, 2008 - NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reported today that excellent efficacy of its EKC-Cide(TM) nanoviricide drug candidate was revealed upon statistical analyses of clinical scores from the first animal study. The EKC-Cide drug candidate clearly demonstrated prevention of conjunctival injection (redness, dilation and prominence of the conjunctival blood vessels) and blepharitis (crusting, discharge and inflammation of the eyelid margins) using mathematical clinical scores calculations. These data confirmed the excellent clinical response observed earlier in eye photographs. In contrast, the control group which received an inactive drop preparation ("negative control") displayed statistically significant higher clinical scores consistent with the expected... [read full story]